What Did You Miss at the 3rd Spatial Biology for Drug Development Summit?
Spatial biology is at a turning point. Rapid advances in resolution, sensitivity, and multi-omics integration are delivering more robust and clinically meaningful insights than ever before. Recent collaborations and investments, such as GSK’s partnership with Relation Therapeutics and Sanofi’s expanded partnership with Owkin, highlight the strong momentum and confidence building across the sector. Yet, challenges around data standardization, integration, scalability, and cost continue to limit widespread adoption, particularly among small and mid-sized biopharma companies.
The 3rd Spatial Biology for Drug Development Summit was your opportunity to come together with industry experts to address these barriers head-on. The 2025 meeting connected leading biopharma, technology providers, and thought leaders to share practical examples, proven strategies, and clear value stories that demonstrate how spatial biology can deliver return on investment across discovery, translational research, and clinical development.
2025 Event Highlights
Tackle
reproducibility and standardization barriers to advance and scale spatial biology from early discovery to real-world impact — accelerating robust, industry-wide adoption
Discover
unprecedented insights into the tumor microenvironment with spatial transcriptomics to reveal novel biomarkers and fuel your therapeutic pipeline
Leverage
advanced computational pipelines to process complex spatial data at scale, delivering deeper insights into tissue architecture for novel breakthroughs
Enable
scalable, integrated data infrastructure to ensure spatial biology is fully interoperable across teams and platforms to save time in your clinical trials
Unlock
smarter spatial biology partnerships to maximize ROI, scale breakthroughs, and bring better treatments to patients faster
Attending Companies Included